Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-8 of 8 (Search time: 0.003 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2008Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALDI-TOF mass spectrometry: Reliable genotyping in different ethnic groupsSchaeffeler, E.; Zanger, U.; Eichelbaum, M.; Asante-Poku, S.; Shin, J.; Schwab, M.
2008TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cellsBuck, M.; Coller, J.; Murdter, T.; Eichelbaum, M.; Knabbe, C.
2008Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trialMorike, K.; Kivisto, K.; Schaeffeler, E.; Jagle, C.; Igel, S.; Drescher, S.; Fux, R.; Marx, C.; Hofmann, U.; Engel, C.; Wagner, F.; Delabar, U.; Meisner, C.; Bail, D.; Bohm, J.; Gleiter, C.; Ziemer, G.; Rein, J.; Hellberg, K.; Eichelbaum, M.; et al.
2008Variability in human hepatic MRP4 expression: Influence of cholestasis and genotypeGradhand, U.; Lang, T.; Schaeffeler, E.; Glaeser, H.; Tegude, H.; Klein, K.; Fritz, P.; Jedlitschky, G.; Kroemer, H.; Bachmakov, I.; Anwald, B.; Kerb, R.; Zanger, U.; Eichelbaum, M.; Schwab, M.; Fromm, M.
2008Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study GroupSchwab, M.; Zanger, U.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb, R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; Bokemeyer, C.; Eichelbaum, M.
2008Breast cancer risk reduction and membrane-bound catechol o-methyltransferase genetic polymorphismsJi, Y.; Olson, J.; Zhang, J.; Hildebrandt, M.; Wang, L.; Ingle, J.; Fredericksen, Z.; Sellers, T.; Miller, W.; Dixon, J.; Brauch, H.; Eichelbaum, M.; Justenhoven, C.; Hamann, U.; Ko, Y.; Bruning, T.; Chang-Claude, J.; Wang-Gohrke, S.; Schaid, D.; Weinshilboum, R.
2008A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancerRokavec, M.; Schroth, W.; Amaral, S.; Fritz, P.; Antoniadou, L.; Glavac, D.; Simon, W.; Schwab, M.; Eichelbaum, M.; Brauch, H.
2008Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancerBrauch, H.; Schroth, W.; Eichelbaum, M.; Schwab, M.; Harbeck, N.